Resistencia a macrólidos, lincosamidas y estreptograminas en infecciones por Streptococcus pneumoniae

Medicina Clinica

Volumn 110, Issue SUPPL. 1, 1998, Pages 25-30

  Alonso Manzanares, Ma Ángeles ^a,b   Gutiérrez Zufiaurre, Ma Nieves ^a   Muñoz Bellido, Juan Luis ^a   García Rodríguez, José Ángel ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; EPEREZOLID; ERYTHROMYCIN; HMR 3004; IMIPENEM; JOSAMYCIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; PENICILLIN G; PRISTINAMYCIN; ROKITAMYCIN; ROXITHROMYCIN; STREPTOGRAMIN DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; LINCOSAMIDE; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; ARTICLE; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VIRGINIAMYCIN;

EID: 0031990063     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. McGuire JM, Bunch RL, Anderson RC, Boaz HE, Flynn EH, Powell HM et al. llotycin, a new antibiotic. Antibiot Chemother 1952; 2: 281-283
2. Pallares R, Gudiol F, Liñares J, Ariza J, Rufi G, Murgui L et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987; 317: 18-22.
3. Dixon JM. Pneumococcus resistant to erythromycin and lyncomicin. Lancet 1967; 1: 573.
4. Gestlin P, Buu-Hoï A- Frémaux A, Acar JF. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970-1990. Clin Infect Dis 1992; 15: 95-98.
5. Dixon JMS, Lipinski AE. Infections with β-hemolytic Streptococcus resistant to lyncomicin and erythromycin and observations on zonal-pattern resistance to lyncomicin. J Infect Dis 1974; 130: 351-356.
6. Marton A, Gulyas M, Muñoz R. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991; 163: 542-548.
7. Liñares J Antibiotic resistant pneumococci in the 1990s: an overview in Spain. En: Streptococcus pneumoniae. Molecular biology and mechanisms of disease. Update for the 1990s. Libra de resúmenes. Oeiras, 1996.
8. Reinert RR, Queck A, Kaufhold A. Kresken M, Lütticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany. Clin Infect Dis 1995; 21: 1.398-1.401.
9. Nissinen A, Leinonen M, Huovinen P, Herva E, Katila ML, Kontiainen S et al. Antimicrobial resistance of Streptococcus pneumoniae in Finland, 1987-1990. Clin Infect Dis 1995; 20: 1.275-1.280
10. Koornhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae. A South African perspective Clin Infect Dis 1992; 15:84-94.
11. Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother 1994; 38: 2.902-2.904
12. Hardy DJ, Hensly DN, Beller JM, Vojtko C, McDonald EJ, Fernandes BP. Comparative in vitro activities of new 14-15, and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32: 1.710-1.719.
13. Franklin TJ, Snow CA. Biochemistry of antimicrobial action. Londres: Chapman and Hall, 1981; 128.
14. Barrière JC, Bouanchaud DH, Paris JM, Rolin O, Harris NV, Smith C. Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds. J Antibiot Chemother 1992; 30 (Supl A): 1-8.
15. Low DE. Quinupristin-dalfopristin: spectrum of activity, pharmacokinetics. and initial clinical experience. Microb Drug Resist 1995; 3: 223-233.
16. Aumercier M, Bouhallab S, Capmau ML, Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J Antibiot Chemother 1992; 20 (Supl A): 9-14.
17. Barry AL, Fuchs PC. In vitro activities of a streptogramin (RP 59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 1995; 39: 238-239
18. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1.267-1.272.
19. Chabbert YA, Courvalin P. Synergie des composants des antibiotiques du groupe de la streptogramine. Pathol Biol 1986; 19: 613-619.
20. Dubnau D, Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. Crit Rev Biochem 1984; 16; 103-132.
21. Eady EA, Ross JI, Cove JH. Multiole mechanisms of erythromycin resistance. J Antimicrob Chemother 1990; 26: 461-471.
22. Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphilococci. Trends Microbiol 1994; 2: 343-347.
23. Ariza RR, Cohen SB, Bachhawat N, Levy SB, Demple B. Repressor mutations in the marRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli. J Bacteriol 1994; 176: 143-148.
24. Leclerq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991; 35: 1.273-1.276.
25. Oleinick NL. The erythromycin. En: Corcoran JW, Hahn FE, editores. Mechanisms of action of antimicrobial and antitumor agents. Nueva York: Springer Verlag, 175-396.
26. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996, 40: 1.817-1.824.
27. Courvalin P, Carlier C. Transposable multiple antibiotics resistance in Streptococcus pneumoniae. Mol Gen Genet 1986; 205: 291-297.
28. Seppälä H, Nissinen A, Järvinen H. Resistance to erythromycin in group A streptococci. N Engl J Med 1992; 326: 292-297.
29. Pérez Trallero E, Garcia Arenzana JM, Urbieta Engaña M. Erythromycin resistance in streptococci. Lancet 1989; 2: 444-445.
30. Fenoll A, Matín Bourgon C, Muñoz R, Vicioso D, Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain 1979-1989. Rev Infect Dis 1991; 13: 56-60.
31. Sempere MA, Gómez J, Ruiz J. Resistance of Streptococcus pneumoniae to erythromycin in adults and children. J Antimicrob Chemother 1992; 29: 348-349.
32. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
33. Verhaegen J, Glupczinski Y, Verbist L, Blogie M, Verbiest N, Vandeven J et al. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clin Infect Dis 1995; 20: 1.339-1.345.
34. Kanavaki S, Karabela S, Marinis E. Antibiotic resistance of clinical isolates of Streptococcus pneumoniae in Greece. J Clin Microbiol 1994; 32: 3.056-3.058.
35. Endtzs HP, Peetermans WEC, Bijlmer HA. Low frequency of erythromycin-resistant Streptococcus pneumoniae in the Netherlands. Lancet 1989; 1: 1.144-1.145.
36. Olsson-Liljequist B, Burman KG, Kallings Y, and the Swedish Respiratory Tract Study Group. Antibiotic susceptibility of upper respiratory tract pathogens in Sweden: a seven year follow-up study including loracarbef. Scand J Infect Dis 1992; 24: 485-493.
37. Breiman RF, Buteler JC, Tenover FC. Emergence of drug resistant pneumococcal infections in the United States, JAMA 1994; 271: 1.831-1.835.
38. Klugman KP. Pneumococcal resistance to antibiotic. Clin Microbiol Rev 1990; 3: 171-196.
39. Lee HJ, Park YY, Jang SH, Kim JH, Kim EN, Choi KW. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis 1995; 20: 826-835.
40. Jones RN, Biedenbach DJ. Antimicrobial activity of RU 66647, a new ketolide. Diagn Microbiol Infect Dis 1997; 27: 7-12.
41. Agouridas C, Collette P, Mauvais P, Chantot JF. RU 004: preliminary studies on the mechanism of action. 35th International Conference on Antimicrobial Agents and Chemotherapy. Libro de Resúmenes. Nueva Orleans, 1996[resumen F170].
42. Agouridas C, Bonnefoy A, Braham K, Collette P, Guitton M, Hochet A et al. RU 004: uptake by phagocytes, intracellular bioactivity and other immunomodulatory effects. 35th International Conference on Antimicrobial Agents and Chemotherapy. Libro de Resúmenes. Nueva Orleans, 1996 [resumen F175].
43. Labbe G, Abecassis PY, Courtin O, Flor M, Fougeat S, Bode G. RU 004: in vitro and in vivo effects on hepatic cytochrome P450. 35th International Conference on Antimicrobial Agents and Chemotherapy. Libro de Resúmenes. Nueva Orleans, 1996 [resumen F174].
44. Ednie LM, Spangler SK, Jacobs MR, Appelbaum PC. Activity of the ketolide RU 004 compared to 15 other agents againts 228 erythromycin susceptible and resistant pneumococci. 3rd International Conference On The Macrolide. Azalides And Streptogramins. Libro de resúmenes. Lisboa, 1996 [resumen 3.19].
45. Frémaux A, Sissia G, Chantot JF, Geslom P. Antibacterial activity of the ketolide RU 004 against multirresistant pneumococci. 35th International Conference on Antimicrobial Agents and Chemotherapy. Libro de Resúmenes. Washington, 1995 [resúmenes F160].
46. Schúlin T, Wennersten CB, Moellering RC, Eliopoulos GM. In vitro activity of RU 54004, a new ketolide antibiotic against gram-positive bacteries. Antimicrob Agents Chemother 1997; 41: 1.196-1 202.
47. Ednie LM, Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 228 penicillin-and erythromycin- susceptible and-resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents. Antimicrob Agents Chemother 1997; 41: 1.033-1.036.
48. Agouridas C, Bonnefoy A, Chantot JF. In vitro antibacterial activity of ketolide RU 004 against respiratory pathogens. 3rd International Conference On The Macrolide, Azalides And Streptogramins. Libro de resúmenes. Lisboa, 1996 [resumen 3.20].
49. Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 1994; 38: 2.065-2.072.
50. Spangler SK, Jacobs MR, Appelbaum PC Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992; 36: 856-859.
51. Nougayrede A, Berthaud N, Bouanchaud DH. Postantibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother 1992; 30(Supl A): 101-106.
52. Jacobs MR, Spangler SK, Appelbaum PC. Effects of macrolide resistance on the activity of the oral straptogramin RPR 106972 and its components against Streptococcus pneumoniae. 3rd International Conference On The Macrolide, Azalides And Streptogramins. Libro de resúmenes. Lisboa, 1996 [resumen 3.18].
53. Slee AM, Wuonola MA, McRipley RJ, Zajac Y, Zawada MJ, Bartholomnw PT et al. Oxazolidinones, a new class of synthetic antibacterials: in vitro and in vivo activities of DuP 105 and DuP 721. 27th International Conference on Antimicrobial Agents and Chemotherapy. Libro de Resúmenes. Washington, 1987 [resumen F170]
54. Slee AM, Wuonola MA, McRipley RJ, Zajac Y, Zawada MJ, Bartholomnw PT et al. Oxazolidinones, a new class of synthetic antibacterials agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987; 31: 1.791-1.797.
55. Daly JS, Eliopoulis GM, Willey S, Moellering RC. Mechanisms of action and in vitro and in vivo activities of S-6123, a new oxazolidinones components. Antimicrob Agents Chemother 1988; 32: 1.341-1.346.
56. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glikman SE et al. In vitro activities of U-100592 and U-100766, novel oxazolidinones antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-845.
57. Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson K, Barbachyn MR et al. Oxazolidinones: new antibacterial agents. Trends Microbiology 1997; 5: 96-200.
58. Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 1996; 40: 720-726.
59. Brumfitt W, Hamilton-Miller JMT. In vitro microbiological activites of DuP 105 and DuP 721, novel synthetic oxazolidinones. J Antimicrob Chemother 1988; 21: 711-720.